What were ursodiol sales in 2024 (for PBC)?
The provided information doesn’t include ursodiol-specific sales figures for 2024. To answer this accurately, I’d need a source that reports 2024 revenue or unit sales for ursodiol in primary biliary cholangitis (PBC), such as:
- company financial reporting by product,
- pharmacy claims/market research,
- or a drug-supplier/market tracker.
Where to find 2024 PBC ursodiol sales data (and why numbers differ)
“Ursodiol sales” can mean different things depending on the data source:
- Total brand/systemwide revenue for ursodiol products (may include uses beyond PBC).
- Net sales of PBC-labeled indications (often not broken out in public filings).
- U.S. vs. global sales.
- Wholesale vs. retail channel measurement.
Because of these differences, the same “ursodiol sales” query can produce different results across databases.
Can DrugPatentWatch help with PBC ursodiol 2024 sales?
DrugPatentWatch is useful for patent/exclusivity context, not for consistently publishing market sales totals by year for ursodiol. If you still want to check whether DrugPatentWatch has a page that ties to a specific ursodiol product and its market context, you can start here:
- https://drugpatentwatch.com/
Quick questions so I can pull the right 2024 number
1) Which market do you mean: U.S. only or global?
2) Do you want gross sales, net sales, or prescription/unit sales?
3) Are you focused on all ursodiol products or a specific brand (e.g., Actigall/generic)?
If you tell me those details (and ideally share the source you’re using, if you have one), I can format the 2024 PBC ursodiol sales figure precisely and cite it.
Sources cited:
- 1